Drug Profile


Alternative Names: Galnobax; VLD-02

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NovaLead Pharma Pvt. Ltd
  • Class Antiarrhythmics; Antihypertensives
  • Mechanism of Action Beta 1 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Diabetic foot ulcer

Highest Development Phases

  • Phase I/II Diabetic foot ulcer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 21 Jan 2016 Esmolol is available for licensing as of 21 Jan 2016.
  • 21 Jan 2016 NovaLead Pharma completes a phase I/II trial in Diabetic foot ulcer in USA, India and Malaysia prior to this date (NCT01113515)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top